Related Experiment Video
Updated: Apr 11, 2026
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
Milk derived colloid as a novel drug delivery carrier for breast cancer
Masamichi Hayashi1, Nissim Silanikove, Xiaofei Chang
1a Department of Otolaryngology-Head and Neck Surgery ; Johns Hopkins School of Medicine ; Baltimore , MD USA.
Abstract:
Triple negative breast cancer has an extremely poor prognosis when chemotherapy is no longer effective. To overcome drug resistance, novel drug delivery systems based on nanoparticles have had remarkable success. We produced a novel nanoparticle component 'MDC' from milk-derived colloid. In order to evaluate the anti-cancer effect of MDC, we conducted in vitro and in vivo experiments on cancer cell lines and a primary tumor derived breast xenograft. Doxorubicin (Dox) conjugated to MDC (MDC-Dox) showed higher cancer cell growth inhibition than MDC alone especially in cell lines with high EGFR expression. In a mouse melanoma model, MDC-Dox significantly suppressed tumor growth when compared with free Dox. Moreover, in a primary tumor derived breast xenograft, one of the mice treated with MDC-Dox showed partial regression, while mice treated with free Dox failed to show any suppression of tumor growth. We have shown that a novel nanoparticle compound made of simple milk-derived colloid has the capability for drug conjugation, and serves as a tumor-specific carrier of anti-cancer drugs. Further research on its safety and ability to carry various anti-cancer drugs into multiple drug-resistant primary breast models is warranted.
Insights
Researchers developed a novel nanoparticle, MDC, from milk-derived colloid to deliver chemotherapy drugs. MDC-conjugated doxorubicin (MDC-Dox) effectively inhibited triple-negative breast cancer growth in preclinical models, offering a promising strategy against drug resistance.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Oncology
Background:
- Triple-negative breast cancer (TNBC) presents a poor prognosis, particularly when chemotherapy resistance develops.
- Nanoparticle-based drug delivery systems show promise in overcoming chemotherapy resistance.
- A novel nanoparticle component, MDC, was synthesized from milk-derived colloid.
Purpose of the Study:
- To evaluate the anti-cancer effects of the novel milk-derived colloid nanoparticle (MDC).
- To assess the efficacy of doxorubicin conjugated to MDC (MDC-Dox) against cancer cell lines and in vivo tumor models.
Main Methods:
- In vitro experiments were conducted on cancer cell lines, including those with high EGFR expression.
- In vivo studies involved a mouse melanoma model and a primary tumor-derived breast xenograft model.
- MDC-Dox efficacy was compared against MDC alone and free doxorubicin (Dox).
Main Results:
- MDC-Dox demonstrated superior cancer cell growth inhibition compared to MDC alone, especially in EGFR-high expressing cell lines.
- MDC-Dox significantly suppressed tumor growth in a mouse melanoma model versus free Dox.
- In a breast xenograft model, MDC-Dox induced partial tumor regression in one mouse, while free Dox showed no tumor suppression.
Conclusions:
- The novel milk-derived colloid nanoparticle (MDC) can be conjugated with drugs and acts as a tumor-specific carrier.
- MDC-Dox exhibits significant anti-cancer activity, suggesting potential for overcoming drug resistance in TNBC.
- Further research is warranted to explore MDC's safety and efficacy with various anti-cancer drugs in diverse drug-resistant breast cancer models.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
01:24Modified-Release Drug Delivery Systems: Site-Targeted
01:19Modified-Release Drug Delivery Systems: Overview